KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Research & Development (2017 - 2025)

Aquestive Therapeutics has reported Research & Development over the past 9 years, most recently at $3.2 million for Q4 2025.

  • Quarterly results put Research & Development at $3.2 million for Q4 2025, down 35.0% from a year ago — trailing twelve months through Dec 2025 was $17.2 million (down 15.23% YoY), and the annual figure for FY2025 was $17.2 million, down 15.23%.
  • Research & Development for Q4 2025 was $3.2 million at Aquestive Therapeutics, down from $4.5 million in the prior quarter.
  • Over the last five years, Research & Development for AQST hit a ceiling of $5.9 million in Q1 2024 and a floor of $2.9 million in Q4 2023.
  • Median Research & Development over the past 5 years was $4.3 million (2021), compared with a mean of $4.3 million.
  • Biggest five-year swings in Research & Development: soared 70.26% in 2024 and later crashed 35.0% in 2025.
  • Aquestive Therapeutics' Research & Development stood at $4.4 million in 2021, then fell by 2.77% to $4.3 million in 2022, then plummeted by 32.49% to $2.9 million in 2023, then skyrocketed by 70.26% to $4.9 million in 2024, then crashed by 35.0% to $3.2 million in 2025.
  • The last three reported values for Research & Development were $3.2 million (Q4 2025), $4.5 million (Q3 2025), and $4.1 million (Q2 2025) per Business Quant data.